The following summarises some key points from a November 2024 article published on BioPharma Boardroom. I have chosen to focus on aspects that I view as potentially relevant to Neuren. For those who prefer a summary of the summary, the 2025 M & A outlook is positive for Neuren!
2025 M&A Outlook: Transforming Biopharma and Biotech Through Strategic Innovation
2024 as a Springboard for 2025
Key trends seen in 2024, such as the focus on rare diseases, are expected to intensify in 2025.
M&A Activity in 2024: A Year of Strategic Moves
Twelve pivotal transactions in 2024, said to signal the industry’s direction, are highlighted in the article. Four of these transactions involved rare disease assets (see those deals below). Lundbeck’s US$2.6bn acquisition of Longboard Pharmaceuticals, a clinical-stage rare neurology disease company, was not included, probably due to timing.
Amgen Acquires Horizon Therapeutics Value: $28 billion
Details: Amgen’s purchase of Horizon Therapeutics is a masterstroke in diversifying its portfolio. Horizon’s expertise in rare autoimmune diseases like thyroid eye disease provides Amgen with access to high-value, low-competition markets. This move reflects a growing trend of targeting rare diseases with high unmet needs.
Novartis Acquires Chinook Therapeutics Value: $3.5 billion
Details: This acquisition enhances Novartis’ focus on nephrology and rare diseases. Chinook’s assets targeting kidney conditions align with Novartis’ strategy to expand in underserved therapeutic areas.
Biogen Acquires Reata Pharmaceuticals Value: $7.3 billion
Details: Diversification is critical for Biogen, and this deal broadens its neurology portfolio. With treatments targeting rare neurological and renal diseases, Biogen is positioning itself for sustained growth in high-value niches.
AstraZeneca Acquires Amolyt Pharma Value: $1.05 billion
Details: Rare endocrine diseases are an emerging frontier, and AstraZeneca’s acquisition of Amolyt Pharma highlights the industry's focus on targeted therapies for underserved populations.
Industry Insights: Strategic Drivers of M&A in 2024
It is argued that a number of the pivotal deals which were transacted in 2024 highlighted the urgency of pharma to acquire late-stage assets ready for commercialization. This is viewed as a tactical pivot— that is, companies are no longer content with early-stage assets; they want near-term revenue generators.
Rare disease was said to have seen a “gold rush”, becoming a hotspot for investment due to premium pricing, high margins, regulatory incentives and limited competition.
Enhanced Drivers of M&A Activity in 2025
With many pharma facing significant revenue shortfalls from patent cliffs, there is pressure for these companies to act decisively.
Pipeline replenishment through acquisition is seen as a likely response to patent cliffs with companies eyeing biotechs with late-stage or market-ready assets to fill gaps quickly.
There is expected to be a focus on CNS disorders and rare diseases for M & A in 2025. These high-growth areas are said to offer strong revenue potential, especially with regulatory incentives on offer for rare disease therapies, such as expedited approvals and extended exclusivity periods.
There is expected to be a shift to faster revenue-generating assets, with companies increasingly pursuing late-stage pipelines to minimize risk and ensure quicker returns on investment.
It is thought that the urgency to maintain competitive pipelines will intensify competition for high-value biotech companies, potentially driving up valuations and fostering bidding wars.
Evolving Deal Structures in 2025
To mitigate risks, acquirers are increasingly structuring deals with contingent payment components.
Beyond traditional acquisitions, joint ventures are gaining traction as a cost-effective strategy.
Sectors Poised for Growth in 2025
Rare Diseases: Niche but Lucrative
Rare diseases are seen as an increasingly attractive sector for investment. Orphan drug designation regulatory incentives such as market exclusivity, tax credits, and expedited approval pathways are particularly appealing and the ability to charge premium prices due to the limited competition and specialized nature of these treatments ensures robust returns.
It is noted that the rare disease space is no longer just about one-off blockbuster therapies. Companies are building entire franchises around rare conditions.
Neurology: Unlocking the Brain’s Potential
Neurological disorders are seen as an emerging critical area of focus and an attractive M & A target.
Emerging Trends in 2025: Shaping the Future of M&A
A strategic pivot in M & A is seen toward innovation, risk mitigation, and collaboration, ensuring companies remain competitive in an evolving global market.
Mid-Cap Biotechs as Prime Targets
Said to be becoming the “darlings of M&A activity”, mid-cap biotechs are seen to offer an attractive balance between innovation and risk. Mid-cap biotech companies with advanced-stage assets, strong pipelines and focused therapeutic expertise can offer near-term revenue potential and lower development risks.
Mid-cap companies are said to excel in niche areas such as rare diseases.
Large pharma are increasingly drawn to mid-cap targets to avoid the higher integration complexities associated with mega-mergers while still accessing transformative assets.
Mid-cap biotechs are tipped to represent the "sweet spot" for acquirers in 2025, offering innovation, agility, and the potential for quick market entry without the extended timelines and uncertainties of early-stage development.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)